Durvalumab is an antibody drug that is being developed as an intravenous infusion for the treatment of locally advanced or metastatic UBC. The drug acts in a unique way to stimulate the body’s natural defences that fight the cancer cells. This has the potential to increase survival rates and reduce side effects when compared to current treatment options.
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line
Interventions:
Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)
Indications:
Bladder cancer
Therapeutic Areas:
Urological Cancer
Year:
2017